Navigation Links
Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company
Date:8/17/2011

NEW YORK, Aug. 17, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed by the Hadassah University Hospital, Israel's foremost medical research center, announced that its portfolio company Enlivex Therapeutics (92% owned by Hadasit Bio) has completed the recruitment of three out of four groups in its Phase I / II clinical trial using its treatment for the reduction of graft versus host disease (GVHD) in patients undergoing bone marrow transplantation.

Based on the current rate of enrollment and high level of safety observed so far, the trial's enrollment is expected to be completed during the next quarter with a total of 12 patients. The trial is being performed in three of Israel's leading hematology medical centers: Hadassah, Tel - Hashomer and Rambam.

The trial is being performed on bone marrow transplant patients, but the results are also relevant to a number of other autoimmune diseases - in which the individual's immune system targets its own organs - as well as inflammatory diseases - such as Multiple Sclerosis and Inflammatory Bowel Disease.  

An external safety committee meets at the end of each dose group to examine the safety of the treatment and has thus far been impressed by initial results showing this to be a promising treatment method and has consistently approved advancement to the next group, while raising the dose.

The Company previously announced the preliminary results from the earlier stages of this trial.  The treatment continued to show promise after analysis of intermediate results. In terms of efficacy, the Company estimates that, if the results received at the end of the trial are consistent with the data received so far, it will have evidence of a significant improvement in patients' health following the use of its treatment in comparison with the current standard treatments administered.
'/>"/>

SOURCE Hadasit Bio-Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
3. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
4. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
5. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
8. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
11. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... Highlighted by Cinryze(TM) [C1 Inhibitor (human)] Commercial Launch --EXTON, Pa., ... reported today its financial results for the fourth quarter and ... include:Operational: , , , ... Inc. (Lev) in October 2008; , ...
... Feb. 24 Mach One Corporation (Pink Sheets: MNCN), ... purchase of Ceres Organic Harvest, Inc. an organic grain ... feed and dairy industries. Ceres Organic Harvest had 2008 ... the stock of Ceres for $8 million in a ...
... (USA) Inc ("MINDSET") a company privately held by MPM ... received a Notice of Allowance in Europe related to ... for the prevention and treatment of memory loss. Drugs ... been approved for the treatment of type II diabetes ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 12Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc. 2Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss 2Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss 3
(Date:4/16/2014)... The "brush border" a densely packed array of ... the cells that line our intestines., Vanderbilt University researchers ... structure, which is critical for absorbing nutrients and defending ... journal Cell , reveal a role for adhesion ...
(Date:4/16/2014)... thoughts and feelings are the result of neurons talking ... of the conversations might not be all that private. Brain ... even participating in, some of those discussions. But a new ... part of the time specifically, when the neurons get ...
(Date:4/16/2014)... to conquer the world? Surprisingly, bacteria also face this ... now shown how these organisms should decide how best ... subtilis is quite adaptable. It moves about in ... Alternatively, it can stick to an underlying substrate. Actually, ...
Breaking Biology News(10 mins):Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 3Eavesdropping on brain cell chatter 2Eavesdropping on brain cell chatter 3Theoretical biophysics: Adventurous bacteria 2
... German . , Tobias Brgmann and his colleagues from the ... for their experiments, which is a type of light sensor. At ... the cell membrane. When stimulated with blue light, this channel opens, ... in the cell membrane,s pressure, which stimulates cardiac muscle cells to ...
... towards the poles almost everywhere in the world, except ... and snails Steffen Kiel and Sven Nielsen at the ... pattern originated at the end of the last ice ... created a mosaic landscape of countless islands, bays and ...
... rich in walnuts and walnut oil may prepare the body ... Penn State researchers who looked at how these foods, which ... stress., Previous studies have shown that omega-3 fatty acids -- ... seeds -- can reduce low density lipoproteins (LDL) -- bad ...
Cached Biology News:Bonn researchers use light to make the heart stumble 2Disappearing glaciers enhanced biodiversity 2Walnuts, walnut oil, improve reaction to stress 2Walnuts, walnut oil, improve reaction to stress 3
Request Info...
... Source: E. coli containing a clone of ... Description: Topoisomerase II alters the topological state ... helix through a transient break which generates a ... of its double-stranded DNA passage mechanism, the enzyme ...
Request Info...
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
Biology Products: